Supportive Care in Cancer

, Volume 27, Issue 3, pp 927–931 | Cite as

The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients

  • Ana Luísa de Castro BaccarinEmail author
  • Macilon Nonato Irene
  • Daniel de Iracema Gomes Cubero
  • Ariana Sales Luz
  • Suelen Nastri Castro
  • Renan Sordi
  • Luis Eduardo Silva Móz
  • Auro Del Giglio
Original Article



Patients with breast cancer who receive weekly paclitaxel therapy may experience deleterious effects associated with prophylactic dexamethasone use for 12 consecutive weeks. Approximately 90% of paclitaxel hypersensitivity reactions (HSRs) occur within the first 10 to 15 min of the first two infusions. We investigated the feasibility of dexamethasone withdrawal between weeks 3 and 12 (W3 and W12) in early stage breast cancer patients treated with weekly paclitaxel at the standard dose (80 mg/m2).


All patients received intravenous prophylaxis of dexamethasone 20 mg, ranitidine 50 mg, and diphenhydramine 50 mg in the first 2 weeks (W1 and W2) of treatment. Provided that no serious (G3/G4) HSRs events occurred, dexamethasone was omitted between W3 and W12, while ranitidine and diphenhydramine were continued. The primary end point was the incidence of any grade HSRs during the treatment period, and the secondary end points were quality of life and weight changes.


Twenty-five patients were included in the study, and 300 infusion cycles of paclitaxel were evaluated for HSRs. The overall incidence of HSRs was 0.6% (2 events), and both of these events occurred in the first week. There were no incidents of serious HSRs or anaphylaxis and no G3 or G4 toxicities. Scores from the EORTC QLQ-C30 questionnaire did not change significantly for the global health status/quality of life scale or for the symptoms scales, although changes in scores differed significantly for the functional scales. There were no clinically relevant weight changes during the treatment period.


Dexamethasone withdrawal from W3 to W12 in early stage breast cancer patients treated with weekly paclitaxel is feasible. The incidence of all grades of HSRs was comparable to that reported in trials with dexamethasone for 12 consecutive weeks, and no serious events (G3/G4) occurred. Studies with larger sample sizes are needed to confirm our results which are important, especially for patients for whom corticosteroids are contraindicated.


Paclitaxel Hypersensitivity reactions Prophylaxis Dexamethasone 


Compliance with ethical standards

The clinical trial was approved by the Institution’s Ethics Committee.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Picard M, Castells MC (2014) Re-visiting hipersensitivity reactions to taxanes: a comprehensive review. Rev Allerg Immunol.
  2. 2.
    Weiss RB et al (1992) Hypersensitivity reactions. Semin Oncol 19(5):458–477Google Scholar
  3. 3.
    Banerji A et al (2014) Management of hypersensitivity reactions to carboplatin and paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2(4):428–433CrossRefGoogle Scholar
  4. 4.
    Robinson JB et al (2001) Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynaecologic malignancies. Gynecol Oncol 82(3):550–558CrossRefGoogle Scholar
  5. 5.
    Sparano JA et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663–1671CrossRefGoogle Scholar
  6. 6.
    Greco FA et al (1999) One-hour paclitaxel infusions: review of safety and efficacy. Cancer J Sci Am 5(3):179–191Google Scholar
  7. 7.
    Tsavaris N et al. A simplified premedication protocol for one-hour paclitaxel infusion in various combinations. J Support Oncol 2005;3(1):77–81Google Scholar
  8. 8.
    Dewaele E et al (2017) Premedication strategy for paclitaxel, still an unsolved question after years. Belg J Med Oncol 11(2):46–55Google Scholar
  9. 9.
    Green MC et al. Rates of adverse events with low-dose dexamethasone (Dex) as premedication of weekly paclitaxel (Pac) utilized as adjuvant/neoadjuvant therapy for operable breast cancer. Program and abstracts of the American Society of Clinical Oncology 2009 Breast Cancer Symposium; Abstract 307Google Scholar
  10. 10.
    Braverman AS et al (2005) Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration. Chemotherapy 51(2–3):116–119CrossRefGoogle Scholar
  11. 11.
    Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D (2002) Premedication strategy for weekly paclitaxel. Cancer Investig 20:666–672CrossRefGoogle Scholar
  12. 12.
    Koppler H et al (2001) Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie 24(3):283–285 English, GermanGoogle Scholar
  13. 13.
    Lenz HJ et al (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12(5):601–609CrossRefGoogle Scholar
  14. 14.
    Berger MJ et al (2015) Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 23(7):2019–2024CrossRefGoogle Scholar
  15. 15.
    National Cancer Institute (US). Division of cancer treatment and diagnosis. Common toxicity criteria (Computer Program). Version v4.03: June 14, 2010. NCIGoogle Scholar
  16. 16.
    Aaronson NK et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefGoogle Scholar
  17. 17.
    Klee M et al (1997) Quality of life of Danish women: population based norms for the EORTC QLQ-C30. Qual Life Res 6:27–34CrossRefGoogle Scholar
  18. 18.
    Ricci MD et al (2014) Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer. Rev Bras Ginecol Obstet 36(11):503–543CrossRefGoogle Scholar
  19. 19.
    Chauhan N et al (2015) Comparative study of quality of life in breast cancer patients receiving two different chemotherapy regimens using European Organization for Research and Treatment of Cancer Quality of Questionnaire-Core 30 questionnaire module for tolerability and safety. Int J Basic Clin Pharmacol 4(4):664–672CrossRefGoogle Scholar
  20. 20.
    Stone P et al (1998) Fatigue in patients with cancer. Eur J Cancer 34(11):1670CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Ana Luísa de Castro Baccarin
    • 1
    Email author
  • Macilon Nonato Irene
    • 1
  • Daniel de Iracema Gomes Cubero
    • 2
  • Ariana Sales Luz
    • 1
  • Suelen Nastri Castro
    • 1
  • Renan Sordi
    • 1
  • Luis Eduardo Silva Móz
    • 1
  • Auro Del Giglio
    • 3
  1. 1.Instituto Brasileiro de Controle do CâncerSão PauloBrazil
  2. 2.Faculdade de Medicina do ABCSanto AndréBrazil
  3. 3.Faculdade de Medicina do ABC (Chief)São PauloBrazil

Personalised recommendations